Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03761784 · ClinicalTrials.gov registry record · Phase 3
A Study of S6G5T-3 in the Treatment of Acne Vulgaris
A Phase 3 study, sponsored by Sol-Gel Technologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 424
- Enrollment target
NCT03761784: Completed Phase 3 study, sponsored by Sol-Gel Technologies.
NCT03761784 is a Phase 3 study that has completed, run by Sol-Gel Technologies. The registered enrollment target is 424 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03761784, a Phase 3 study, has completed, sponsored by Sol-Gel Technologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 424 participants
- Enrollment target
Study Summary
To assess the efficacy of S6G5T-3 compared to its Vehicle when applied once daily for 12 weeks in participants with acne vulgaris.
Primary Outcome
Percentage of participants in each treatment group achieving an acne severity IGA score of "clear (score=0)" or "almost clear (score=1)" and achieving an acne severity IGA score of at least 2 grades less than Baseline.
Interventions
- DRUG S6G5T-3
- DRUG S6G5T-8
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 424 participants |
| Start Date | 2018-12-21 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 3 |
What the finished NCT03761784 record still lists
NCT03761784 is an interventional study that assigns participants to a tested intervention. The registered 424 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower).
The record links to 0 conditions, and to 2 interventions - of which S6G5T-3 is the first listed.
NCT03761784 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03761784 about?
NCT03761784 is a clinical study titled "A Study of S6G5T-3 in the Treatment of Acne Vulgaris". To assess the efficacy of S6G5T-3 compared to its Vehicle when applied once daily for 12 weeks in participants with acne vulgaris.
What is the current status of trial NCT03761784?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 424 participants. The study started on 2018-12-21. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT03761784?
The interventions under investigation include: S6G5T-3 (DRUG), S6G5T-8 (DRUG).
Who is sponsoring clinical trial NCT03761784?
This trial is sponsored by Sol-Gel Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03761784's enrollment target sits among peer trials
424 884th of 2000 higher than 1,116 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05632770 · 424 participants · NA
A Deployment Focused Pragmatic Trial of Optimal Stepped Care Intervention Targeting PTSD and Comorbidity for Acutely Hospitalized Injury Survivors Treated in US Trauma Care Systems
- NCT05733767 · 424 participants · Phase 2
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
- NCT06978127 · 424 participants · NA
Technology Assisted Collaborative Care Intervention to Improve Patient-centered Outcomes in Dialysis Patients
- NCT07140913 · 424 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI